Fady T. Botros

2.8k total citations · 1 hit paper
40 papers, 1.6k citations indexed

About

Fady T. Botros is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Surgery. According to data from OpenAlex, Fady T. Botros has authored 40 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Endocrinology, Diabetes and Metabolism, 25 papers in Molecular Biology and 8 papers in Surgery. Recurrent topics in Fady T. Botros's work include Diabetes Treatment and Management (20 papers), Metabolism, Diabetes, and Cancer (16 papers) and Heme Oxygenase-1 and Carbon Monoxide (9 papers). Fady T. Botros is often cited by papers focused on Diabetes Treatment and Management (20 papers), Metabolism, Diabetes, and Cancer (16 papers) and Heme Oxygenase-1 and Carbon Monoxide (9 papers). Fady T. Botros collaborates with scholars based in United States, Canada and Italy. Fady T. Botros's co-authors include Katherine R. Tuttle, L. Gabriel Navar, Brian Rayner, Mark Lakshmanan, Alan G. Zimmermann, Robert S. Busch, Nader G. Abraham, Hiroyuki Kobori, George Grunberger and Michal L. Schwartzman and has published in prestigious journals such as Journal of the American College of Cardiology, Diabetes Care and Diabetes.

In The Last Decade

Fady T. Botros

40 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial

2018 460 citations Katherine R. Tuttle, Fady T. Botros et al. profile →

Peers

Countries citing papers authored by Fady T. Botros

Since Specialization

Citations

This map shows the geographic impact of Fady T. Botros's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fady T. Botros with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fady T. Botros more than expected).

Fields of papers citing papers by Fady T. Botros

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fady T. Botros. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fady T. Botros. The network helps show where Fady T. Botros may publish in the future.

Co-authorship network of co-authors of Fady T. Botros

This figure shows the co-authorship network connecting the top 25 collaborators of Fady T. Botros. A scholar is included among the top collaborators of Fady T. Botros based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fady T. Botros. Fady T. Botros is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Once‐weekly insulin efsitora alfa: Design and rationale for the QWINT phase 3 clinical development programme 2024 ·Diabetes Obesity and Metabolism ·Richard M. Bergenstal, Athena Philis‐Tsimikas, Carol Wysham, Molly C. Carr, Juliana Bue‐Valleskey, Fady T. Botros, Thomas Blevins, Julio Rosenstock	11
2	Indicators of Kidney Fibrosis in Patients with Type 2 Diabetes and Chronic Kidney Disease Treated with Dulaglutide 2023 ·American Journal of Nephrology ·Katherine R. Tuttle, Jonathan M. Wilson, Yanzhu Lin, Hui-Rong Qian, Federica Genovese, M.A. Karsdal, Kevin L. Duffin, Fady T. Botros	17
3	Dulaglutide and Kidney Function–Related Outcomes in Type 2 Diabetes: A REWIND Post Hoc Analysis 2023 ·Diabetes Care ·Fady T. Botros, Hertzel C. Gerstein, Raleigh Malik, Claudia Nicolay, (unknown), (unknown), Helen M. Colhoun, Jonathan E. Shaw	17
4	Effect of once weekly dulaglutide by baseline beta‐cell function in people with type 2 diabetes in the AWARD programme 2018 ·Diabetes Obesity and Metabolism ·Chantal Mathieu, Stefano Del Prato, Fady T. Botros, Vivian T. Thieu, Imre Pávó, Nan Jia, Axel Haupt, Chrisanthi A. Karanikas, Luis‐Emilio García‐Pérez	15
5	Effects of Dulaglutide and Insulin Glargine on Estimated Glomerular Filtration Rate in a Real-world Setting 2018 ·Clinical Therapeutics ·Kristina S. Boye, Reema Mody, Jianmin Wu, Maureen J. Lage, Fady T. Botros, Brad Woodward	4
6	Glucagon-Like Peptide-1 Receptor Agonist Use and Renal Impairment: A Retrospective Analysis of an Electronic Health Records Database in the U.S. Population 2018 ·Diabetes Therapy ·Kristina S. Boye, Fady T. Botros, Axel Haupt, Brad Woodward, Maureen J. Lage	18
7	Baseline factors associated with glycaemic response to treatment with once‐weekly dulaglutide in patients with type 2 diabetes 2016 ·Diabetes Obesity and Metabolism ·Carol Wysham, Bruno Guerci, David A. D’Alessio, Nan Jia, Fady T. Botros	14
8	Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events 2016 ·Cardiovascular Diabetology ·Keith C. Ferdinand, Fady T. Botros, Charles Atisso, Philip T. Sager	49
9	Prorenin receptor in distal nephron segments of 2-kidney, 1-clip goldblatt hypertensive rats. 2013 ·PubMed ·Minolfa C. Prieto, Fady T. Botros, (unknown), L. Gabriel Navar	20
10	Tadalafil for the Treatment of Pulmonary Arterial Hypertension 2012 ·Journal of the American College of Cardiology ·Ronald J. Oudiz, Bruce H. Brundage, Nazzareno Galiè, Hossein Ardeschir Ghofrani, Gérald Simonneau, Fady T. Botros, Melanie Chan, Anthony Beardsworth, Robyn J. Barst	103
11	Monotherapy with the once‐weekly GLP‐1 analogue dulaglutide for 12 weeks in patients with Type 2 diabetes: dose‐dependent effects on glycaemic control in a randomized, double‐blind, placebo‐controlled study 2012 ·Diabetic Medicine ·George Grunberger, Amelia Chang, Guadalupe Sòria, Fady T. Botros, (unknown), Zvonko Miličević	90
12	Bilirubin Exerts Renoprotective Effects in Angiotensin II-Hypertension 2010 ·The American Journal of the Medical Sciences ·(unknown), L. Gabriel Navar, Fady T. Botros, Mónika Göőz	14
13	Collecting duct renin: a major player in angiotensin II–dependent hypertension 2009 ·Journal of the American Society of Hypertension ·Minolfa C. Prieto‐Carrasquero, Fady T. Botros, Hiroyuki Kobori, L. Gabriel Navar	63
14	Collecting Duct Renin Is Upregulated in Both Kidneys of 2-Kidney, 1-Clip Goldblatt Hypertensive Rats 2008 ·Hypertension ·Minolfa C. Prieto‐Carrasquero, Fady T. Botros, (unknown), Hiroyuki Kobori, Dale M. Seth, Dulce Elena Casarini, L. Gabriel Navar	95
15	Heme oxygenase induction attenuates afferent arteriolar autoregulatory responses 2008 ·American Journal of Physiology-Renal Physiology ·Fady T. Botros, Minolfa C. Prieto‐Carrasquero, (unknown), L. Gabriel Navar	11
16	Intrarenal renin-angiotensin system and counteracting protective mechanisms in angiotensin II-dependent hypertension 2007 ·Acta Physiologica Hungarica ·Kenneth D. Mitchell, Fady T. Botros, L. Gabriel Navar	14
17	Interaction between endogenously produced carbon monoxide and nitric oxide in regulation of renal afferent arterioles 2006 ·American Journal of Physiology-Heart and Circulatory Physiology ·Fady T. Botros, L. Gabriel Navar	44
18	Genetic suppression of HO-1 exacerbates renal damage: reversed by an increase in the antiapoptotic signaling pathway 2006 ·American Journal of Physiology-Renal Physiology ·Rafał Olszanecki, Rita Rezzani, Shinji Omura, David E. Stec, Luigi Fabrizio Rodella, Fady T. Botros, Alvin I. Goodman, George I. Drummond, Nader G. Abraham	33
19	Increase in heme oxygenase-1 levels ameliorates renovascular hypertension 2005 ·Kidney International ·Fady T. Botros, Michal L. Schwartzman, Charles T. Stier, Alvin I. Goodman, Nader G. Abraham	92
20	Regulation of Cyclooxygenase- and Cytochrome P450-Derived Eicosanoids by Heme Oxygenase in the Rat Kidney 2002 ·Hypertension ·Fady T. Botros, Michal L. Schwartzman, Nader G. Abraham	45

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact